Share Incentive Plans - The total number of shares available for issuance under the 2023 Equity Incentive Plan is 5,000,000 shares, accounting for approximately 2.84% of the company's issued shares as of the 2023 annual report date [6]. - The maximum number of H shares under the H Share Reward and Trust Plan is 10,420,000 shares, representing about 5.92% of the total share capital as of the 2023 annual report date [7]. - The percentage of shares available for issuance under the existing share incentive plans is zero, as all 5,000,000 restricted shares have been granted [3]. Disclosure Errors - The company corrected a disclosure error regarding 150,000 restricted shares, clarifying that there were zero shares canceled and 150,000 shares that had lapsed during the reporting period [13]. - The main reason for the disclosure error was the lack of clarity in the share incentive plan regarding the classification of restricted shares as "canceled" or "lapsed" [14]. Compliance and Internal Controls - The company plans to strengthen internal controls related to the share incentive plan, including quarterly reviews of grant details and monitoring of vesting schedules [15]. - The company will conduct a comprehensive review of the existing share plan to ensure compliance with the latest listing rules and provide training for key personnel on relevant regulations [17]. Shareholder Actions - Dr. Liang Dongke received a maximum allocation of 83,400 restricted shares under the share incentive plan, which exceeded his personal limit, violating Listing Rule 17.03C(3) [12]. - The board will seek shareholder approval to increase Dr. Liang's personal limit and amend the share incentive plan to clarify the status of voluntarily lapsed restricted shares [19].
康德莱医械(01501) - 2024 - 年度业绩